Pharmaceutical sponsor
Sichuan Huiyu Pharmaceutical Co., Ltd Clinical Trials
Studies where Sichuan Huiyu Pharmaceutical Co., Ltd is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 10Solid Tumor
A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes
This is a multi-center , open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK) characteristics of HYP-6589 in monotherapy in advanced solid tumors and combination with tyrosine kinase inhibitors…
- Trial name
- NCT06712680
- Testing
- Test Product HYP-6589, Osimertinib
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Safety, Tolerability
Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.
- Conditions
- Safety, Tolerability, Efficacy
- Trial name
- NCT06639256
- Testing
- Test Product HY07121
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Breast Cancer
Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer
This study was a multicenter, randomized, open, single-dose, two-cycle, two-cross-dosing human bioequivalence trial designed to evaluate the bioequivalence of tested and reference preparations in breast cancer subjects.
- Trial name
- NCT06765590
- Testing
- T, 260 mg/m2, paclitaxel for injection (albumin-bound), R, 260 mg/m2, paclitaxel for injection (albumin bound).
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Healthy Adult
Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions
The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in healthy participants under fasting condition.
- Trial name
- NCT07606105
- Testing
- Ferric Carboxymaltose Injection, Ferric Carboxymaltose Injection [Injectafer®]
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Iron Deficiency Anemia
A Study of Ferric Derisomaltose Injection in Chinese Participants With Iron Deficiency Anemia Under Fasting Conditions
The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in participants with iron deficiency anemia under fasting condition.
- Trial name
- NCT07790562
- Testing
- Ferric Derisomaltose Injection, Ferric Derisomaltose Injection [MonoFer®]
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Safety, Tolerability
Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors
This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 for Injection (Subcutaneous) in participants with advanced solid…
- Conditions
- Safety, Tolerability, Efficacy
- Trial name
- NCT07789327
- Testing
- Test Product HY07121 for Injection (Subcutaneous)
- Volunteers
- 254 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Moderate or Severe Submental Fullness
A Phase I Study of HY-2003 in the Subjects With Excessive Submental Fat Accumulation
The main purpose of this study is to evaluate the safety of HY-2003 in subjects with moderate to severe submental fat accumulation at different doses and dosing frequencies in comparison with the positive control and placebo.
- Trial name
- NCT06756490
- Where
- 2 sites in China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Solid Tumor
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
This is a multicenter, open-label, phase I/Ⅱ study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of HY0001a for injection in participants with advanced solid tumors.
- Trial name
- NCT07069062
- Testing
- Test product HY0001a for injection
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Safety, Tolerability
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
This is a multicenter, open-label phase 1/2 study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of…
- Conditions
- Safety, Tolerability, Efficacy
- Trial name
- NCT06243354
- Testing
- Test product: HYP-2090PTSA
- Where
- 6 sites in China
- Volunteers
- 257 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Advanced Solid Tumor
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced…
- Trial name
- NCT07083323
- Testing
- HY05350 for injection
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd